RxDoctor Payments Data

Gilberto de Miranda Aqu, MD

General Practice · Santurce, PRNPI 1316940943

Payments from drug & device makers

$846in general payments, 2019–2025

Across 32 payments — averaging $26.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$166
  • Bayer$154
  • Johnson & Johnson$100
  • Chiesi USA, Inc.$81
  • Abbott$80
  • Exact Sciences$71
  • plus $194 from 8 others

What the payments were for

  • Food & beverage$846100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$846 in reported general payments places this provider in the 80th percentile of 3,586 general practice providers in Puerto Rico.

See all general practice providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$17,613
Medicare patients
51
Services billed
270

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban50$50,506
JardianceEmpagliflozin26$29,103
RybelsusSemaglutide11$25,110
FarxigaDapagliflozin Propanediol17$20,719
TrulicityDulaglutide13$17,749
LinzessLinaclotide24$16,333
Albuterol Sulfate HfaAlbuterol Sulfate84$2,857
Atorvastatin Calcium322$2,305
Levothyroxine Sodium236$2,226
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$1,550
SynthroidLevothyroxine Sodium13$1,146
Rosuvastatin Calcium143$1,128
Losartan Potassium147$1,013
Metformin Hcl239$1,011
Alendronate Sodium152$979

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$21$50,50650 claims
Boehringer IngelheimJardiance$166$29,10326 claims
Novo NordiskRybelsus$26$25,11011 claims
AstraZenecaFarxiga$15$20,71917 claims
Lilly USA, LLCTrulicity$33$17,74913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,586 general practice providers in Puerto Rico.

Other general practice in Santurce

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →